Medtronic reported strong third quarter (Q3) fiscal 2026 results with its highest enterprise revenue growth in ten quarters. The company’s Q3 revenue increased, reflecting accelerated growth across core business segments. Medtronic continued to invest in research and development to advance its innovation pipeline, funded significant growth opportunities, and drove general and administrative leverage. The company also executed on its mergers and acquisitions and venture strategy with two key transactions during the quarter. Excluding the potential impact from tariffs of approximately USD 185 million, Medtronic projects fiscal year 2026 diluted non-GAAP EPS growth of about 4.5%. Management highlighted continued execution on its roadmap and positioning for sustainable growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602170645PR_NEWS_USPR_____CG88919) on February 17, 2026, and is solely responsible for the information contained therein.